<DOC>
	<DOC>NCT00292084</DOC>
	<brief_summary>This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic hepatitis C genotype 1 infection.</brief_summary>
	<brief_title>An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients who completed HCV05002 only 1865 years of age, inclusive Primary diagnosis of chronic HCV infection Nonresponders to previous pegylated interferonbased therapy Patients naive to interferonbased therapy for chronic HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Celgosivir</keyword>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Non-responders</keyword>
	<keyword>End of Treatment Response</keyword>
	<keyword>Sustained Viral Response</keyword>
</DOC>